These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3201181)

  • 41. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma drug level and clinical response.
    Cooper TB; Volavka J; Czobor P
    J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036
    [No Abstract]   [Full Text] [Related]  

  • 43. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 45. Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?
    König P; Conca A; Lugmayer B
    Neuropsychobiology; 1999 Sep; 40(3):140-1. PubMed ID: 10494049
    [No Abstract]   [Full Text] [Related]  

  • 46. Early response to haloperidol treatment in chronic schizophrenia.
    Stern RG; Kahn RS; Harvey PD; Amin F; Apter SH; Hirschowitz J
    Schizophr Res; 1993 Aug; 10(2):165-71. PubMed ID: 8398949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
    Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
    McDermott BE; Sautter FJ; Garver DL
    Psychiatry Res; 1991 Apr; 37(1):97-103. PubMed ID: 1862165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia.
    Kahn EM; Schulz SC; Perel JM; Alexander JE
    J Clin Psychopharmacol; 1990 Feb; 10(1):54-7. PubMed ID: 2106534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate.
    Altamura AC; Tacchini GL; Maes M
    Eur Neuropsychopharmacol; 1995; 5 Suppl():55-8. PubMed ID: 8775759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
    Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
    Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
    Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
    Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients.
    Rinieris P; Hatzimanolis J; Markianos M; Stefanis C
    Neuropsychobiology; 1989; 22(3):146-9. PubMed ID: 2485861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
    Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
    Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical response and plasma haloperidol levels in schizophrenia.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    Psychopharmacology (Berl); 1983; 81(4):354-6. PubMed ID: 6419263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.